Notice NOT-EY-25-003 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-25-303 from the NIH Guide for Grants and Contracts. The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional NOFO. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity PA-25-305 from the NIH Guide for Grants and Contracts. The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Notice of Funding Opportunity Announcement requires that at lease 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funding Opportunity RFA-OH-25-183 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity Announcement (NOFO) is to solicit meritorious applications from universities with graduate programs in mining and explosives engineering to develop and conduct research specifically focused on aspects of underground mine evacuation technologies and human factors related to mine emergencies.

Funding Opportunity PA-25-301 from the NIH Guide for Grants and Contracts. The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity does not accept applications proposing clinical trial(s).

Funding Opportunity PA-25-307 from the NIH Guide for Grants and Contracts. The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions

Funding Opportunity PA-25-306 from the NIH Guide for Grants and Contracts. The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Notice of Funding Opportunity requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

Funding Opportunity PA-25-304 from the NIH Guide for Grants and Contracts. The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Funding Opportunity PA-25-302 from the NIH Guide for Grants and Contracts. The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Notice of Funding Opportunity does not accept applications proposing clinical trial(s).

Funding Opportunity RFA-DK-26-006 from the NIH Guide for Grants and Contracts. The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere.

Notice NOT-AG-24-093 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-032 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.

Notice NOT-DC-25-021 from the NIH Guide for Grants and Contracts

Notice NOT-HG-25-017 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-315 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy (cART-suppressed), impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mycobacterium tuberculosis (Mtb) or hepatitis B virus (HBV). This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, tuberculosis (TB) and HBV disease progression.

Funding Opportunity PAR-25-316 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support research to elucidate how HIV-induced immunometabolic alterations, in a host suppressed on combination antiretroviral therapy (cART-suppressed), impact the immune response and increase risk for poor outcomes due to a second, potentially long-term, infection such as Mycobacterium tuberculosis (Mtb) or Hepatitis B Virus (HBV). This NOFO aims to support research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, Tuberculosis (TB) and HBV disease progression.

Notice NOT-OD-25-043 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-011 from the NIH Guide for Grants and Contracts

Notice NOT-HS-25-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-327 from the NIH Guide for Grants and Contracts. The Ultra-Rare Gene-Based Therapy (URGenT) network supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing of gene-based or transcript-directed therapeutics, such as oligonucleotides and viral-based gene therapies, for ultra-rare neurological or neuromuscular disorders. The goal of this announcement is to accelerate the development of a promising clinical candidate with robust biological rationale and demonstrated proof of concept (POC) data for the intended approach in a model system relevant to a specified patient population towards an IND filing and the initiation of a clinical trial.